US OptionsDetailed Quotes

HOWL240719P2500

Watchlist

0.15
0.000.00%

15min DelayClose Jul 12 16:00 ET

0.00High0.00Low

Werewolf Therapeutics Stock Discussion

Jaguar8

Jun 1 13:49

NEWS

$Werewolf Therapeutics(HOWL.US)$
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three obje...

Jaguar8

May 23 16:01

$Werewolf Therapeutics(HOWL.US)$
NEWS
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, ...

Trytosaveabit

May 3 06:16

Reminder to make a note!

$Werewolf Therapeutics(HOWL.US)$ Werewolf Therapeutics Inc: Plans to Present Interim, First-in-Human Clinical Data From Ongoing Phase 1 Trial of Wtx-330 in Q2 of 2024

Trytosaveabit

Apr 14 07:01

Watching! Lots of information coming before EO2Q!

$Werewolf Therapeutics(HOWL.US)$ Upcoming Milestones! Most if not all data of some sort is to be released before end of Q2!
WTX-124:
•In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Ph...

Moomoo AI

Jan 30 04:09

Despite Werewolf Therapeutics' stock surge, its modest P/S ratio is justified due to inconsistent revenue growth and forecasted contraction. The weak outlook could continue to impact the share price.

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Shares Bounce 27% But Its Business Still Trails The Industry

Moomoo AI

Jan 4 15:13

Dr. Atkins sees great potential in Werewolf Therapeutics' immunotherapies for cancer treatment. Werewolf Therapeutics' CEO appreciates Atkins' expertise as the company grows.

Press Release: Werewolf Therapeutics Appoints Michael Atkins, M.D., to Its Board of Directors

Moomoo AI

Dec 9, 2023 06:30

Werewolf Therapeutics' revenue performance is uncertain, and it's P/S ratio is low compared to the biotech industry due to potential shrink in revenues. Its low P/S ratio is justified given other companies' revenue growth forecasts, indicating no significant share price rise.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Held Back By Insufficient Growth Even After Shares Climb 28%

Trytosaveabit

Nov 14, 2023 16:35

Nice!

$Werewolf Therapeutics(HOWL.US)$ Werewolf Therapeutics Q3 2023 EPS $(0.23) Up From $(0.40) Revenue $5.897M Beats $1.592M Estimate

Stoic Trader

Nov 3, 2023 22:01

$Werewolf Therapeutics(HOWL.US)$ 👀werewolf in action now with massive buying volume today 🤣 lets hope its not spam in for few small postion

wooper

Nov 3, 2023 08:35

I like pstv only

📈💥 Let's seize Friday! Yesterday we witnessed a ticker surge with a 44.24% LONG MOVE. Today's focus:
✅1️⃣ HOWL Long > 2.73 Short < 2.61
✅2️⃣ NVOS Long > 0.3300 Short < 0.3095
✅3️⃣ CYTO Long > 0.2035 Short < 0.1855
✅4️⃣ PSTV Long > 1.64 Short < 1.49
✅5️⃣ IFRX Long > 1.62 Short < 1.53
✅6️⃣ FUBO Long > 3.20 Short < 2.99

No comment yet